On June 1, 2021 Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapy platforms for the treatment of solid tumors, reported that two PVSRIPO presentations will be made during poster sessions at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held virtually June 4 – 8, 2021 (Press release, Istari Oncology, JUN 1, 2021, View Source [SID1234583317]). PVSRIPO is a viral immunotherapy shown in preclinical studies to activate innate and adaptive immunity to facilitate a polyfunctional antitumor CD8+ T cell response. Clinical trials are underway in recurrent glioblastoma (LUMINOS-101), melanoma (LUMINOS-102) and a range of solid tumors (LUMINOS-103).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting include:
Title: LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma, Abstract #TPS2065
Virtual Session: Central Nervous System Tumors
Dates: June 4 – 8, 2021
Location ASCO (Free ASCO Whitepaper) Virtual Scientific Program
Title: Safety and efficacy of murine PVSRIPO plus anti PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model, Abstract #2560
Virtual Session: Developmental Therapeutics – Immunotherapy
Dates: June 4 – 8, 2021
Location: ASCO (Free ASCO Whitepaper) Virtual Scientific Program
Additional information on the meeting can be found on the ASCO (Free ASCO Whitepaper) website. ASCO (Free ASCO Whitepaper) participants and non-participants can also browse Istari’s virtual medical affairs exhibit at https://istarivirtualexhibit.com/ and learn more about PVSRIPO’s mechanism of action, the LUMINOS clinical trials program, and view published studies and posters to be presented at ASCO (Free ASCO Whitepaper) 2021 and other previous congresses. For more information about Istari Oncology and ongoing clinical trials and research, visit www.istarioncology.com.
About PVSRIPO
PVSRIPO is an investigational immunotherapy based on the live attenuated Sabin type 1 poliovirus vaccine that has been genetically modified for safety. PVSRIPO has a distinct target (the poliovirus receptor, CD155), which is expressed on virtually all solid tumors and antigen-presenting cells. Via CD155, PVSRIPO targets tumors with two primary mechanisms: 1) direct damage to and killing of cancerous cells; and 2) engaging innate and adaptive antitumor immune responses via nonlethal infection of antigen presenting cells in the tumor, which stimulates a specific signaling pathway resulting in a sustained, robust type-I/III interferon-dominant response, with minimal release of unwanted cytokines. Its effects are potentiated by prior vaccination against poliovirus. PVSRIPO has been granted Breakthrough Therapy Designation and Orphan Status by the FDA in recurrent glioblastoma. PVSRIPO has also been granted Orphan Status by the FDA for advanced melanoma.